News

At New Wave Derm 2025, Kalil shared expert tips on evaluating and diagnosing scarring vs non-scarring hair loss using clinical tools.

Vapendavir shows promise in reducing respiratory symptoms and illness duration in COPD patients infected with rhinovirus.

Children with KCN have greater risk of progression than adults; study findings suggest CXL may slow that progression or prevent it altogether.

Hosts explore the latest advancements in amyloidosis treatment, with expert insights on emerging therapies and patient care strategies.

Kalil discusses the latest advancements in hair loss treatments, including innovative therapies and ongoing research in dermatology for effective solutions.

Guan describes the potential value of using wearable devices to enhance IBS management by tracking sleep and exercise.

This interview with Jennifer Soung, MD, highlights the implications of recent phase 3 findings on roflumilast foam 0.3% (Zoryve) for psoriasis of the scalp and body.

Findings suggest a connection between RVO history and cystoid macular edema with the risk of developing postoperative macular edema after uneventful cataract surgery.

Long-term studies reveal that benralizumab achieves sustained remission in severe eosinophilic asthma, significantly reducing exacerbations in older adults.

With the sNDA acceptance, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.

In this retrospective study, investigators highlight the effectiveness and safety of baricitinib and systemic corticosteroid addition for alopecia areata.

Banerjee describes the value of multiorgan MRI for predicting cardiac and liver outcomes and cT1’s prognostic utility in liver disease.

The recent analysis has indicated the implant’s relative success in maintaining treatment for NIU without need for supplementary treatments.

Elevated lipoprotein(a) levels significantly increase the risk of recurrent cardiovascular events, highlighting the need for effective LDL-C-lowering therapies.

In this cross-sectional study, investigators looked at the relationship between neighborhood-level socioeconomic status and hidradenitis suppurativa.

Levy explains the unmet need for effective PSC treatment options and reviews new data from the phase 2 ELMWOOD trial of elafibranor in PSC.

Recent data from the GALE trial align with OAKS and DERBY results, indicating a successful treatment of geographic atrophy.

New research follows a previous landmark study that linked mucus plugs to increased mortality in people with COPD even without hallmark symptoms.

Adult-onset T1D significantly raises cardiovascular disease and mortality risks, highlighting the need for improved management and prevention strategies.

In this analysis, investigators looked at the extent to which psoriasis severity correlates with patients’ risk of developing sleep disorders.

A study reveals CoMiSS effectively monitors symptom improvement in infants with cow's milk allergy during elimination diets, guiding dietary adjustments.

The Amsterdam-Oxford Model successfully predicted adverse outcomes in a US cohort of PSC patients, validating its generalizability.

Goldberg’s post hoc analysis has indicated that AREDS and AREDS2 vitamins do not slow either GA progression to the fovea or overall GA growth.

FDA accepts BioCryst’s NDA for berotralstat oral granules in kids with HAE; priority review granted. Approval could bring first oral prophylactic for kids aged <12 years.

In part 2 of this episode of Crisis Point, 4 experts on pain and opioid misuse discuss continuing efforts to turn the tide.

Anthony Lembo, MD, explains the Vibrating Capsule’s utility in chronic idiopathic constipation and reviews findings from a post hoc analysis of a phase 3 trial.

These findings highlight the potential for JAKi use in alopecia areata in terms of associated neuroimmune dysregulation and comorbidities.